Brought to you by 
Series B for neuro start-up CoLucid raises $25mm
Jul 2008
Executive Summary
First-time backer Care Capital has led the $25mm Series B financing for CoLucid Pharmaceuticals (lead candidate for migraine plus preclinical programs for several other neurological diseases) and contributed a new board member to the company. Returning shareholders Pappas Ventures, Domain Associates, Pearl Street Venture Funds, and Triathlon Medical Ventures also participated. CoLucid will use to money to move its 5HT1F agonist COL144 into Phase III and test the compound's anti-migraine efficacy as an oral medicine.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B for neuro start-up CoLucid raises $25mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice